CN100336526C - Medicine composition for treating diabetes and preparing method - Google Patents

Abstract

The present invention relates to a medicinal composition for reducing blood sugar and treating chronic blood vessel complication of diabetes and a preparation method of the medicinal composition. The medicinal composition of the present invention is mainly made from raw medicinal materials of (by weight portion) 2 to 6 portions of giant knotweed rhizome, 2 to 6 portions of coptis root and 0.5 to 3 portions of cassia bark. The preparation method of the medicine comprises: a) the giant knotweed rhizomes, the coptis roots and the cassia bark are respectively weighed for standby according to weight proportion; b) the giant knotweed rhizomes and the coptis roots are reflowed and extracted by adopting alcohol, powdered extract is formed, and volatile oil is extracted from the cassia bark; c) the volatile oil and the powdered extract are mixed, supplementary materials are added, and an oral taking dosage form is processed. The medicine of the present invention has the action of heat clearing and activation of blood circulation for seekinga temporary solution and the action of kidney invigoration and yuan supporting for effecting a permanent cure, and has outstanding therapeutic effects on chronic blood vessel merged complications, such as non-insulin dependent diabetes merged with blood fat raising, blood rheology abnormal blood rheology, vasomotor dysfunction, etc.

Description

A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof

[technical field]

The present invention relates to the pharmaceutical composition of a kind of blood sugar lowering, treatment diabetes chronic vascular complication, and this preparation of drug combination method, the field of Chinese medicines belonged to.

[background technology]

Diabetes are a kind of common endocrine and metabolic disorders diseases, belong to the traditional Chinese medical science category of " quenching one's thirst ".Along with the aging of world population, diabetes have become commonly encountered diseases, frequently-occurring disease, and according to statistics: the global at present type ii diabetes patient who has diagnosed reaches 1.3 hundred million people, and China has surpassed 4,000 ten thousand people, and sickness rate is rising year by year.Diabetics accounts for 80% by the mortality rate that cardiovascular and cerebrovascular disease causes, and makes its life-span reduce 1/3, and diabetics merges blood fat rising person more than 80%, merges blood viscosity rising person and reaches more than 90%.Mortality rate due to the diabetic microvascular complication such as diabetic nephropathy, diabetic retinopathy and disability rate all are rising situation.Because the death toll that causes of diabetic complication is continue cardiovascular and cerebrovascular disease, cancer after the 3rd in developed country, has caused the attention of countries in the world, numerous and confused pathogenesis to diabetes, medical treatment etc. are studied.

From at present clinical hypoglycemic medicine used or that soon use, various Western medicine also can only blood sugar control, diabetics is merged large and small vascular lesions such as blood fat rising, blood viscosity enhancing, vessel wall thickening sclerosis and do not have obvious effect, and certain limitation and untoward reaction are arranged, or even serious adverse effects, as cause hypoglycemia, lactic acidosis etc.The registered diabetes Chinese patent medicine of declaring of China has nearly 40 kinds, mostly only at " three-many-one-little " symptom of improving diabetes, because of herbal nature relaxes, hypoglycemic effect is rapid-action and lack the market competitiveness not as good as Western medicine, on the location, fail to maximize favourable factors and minimize unfavourable ones, give full play to the advantage of Chinese medicine on the treatment chronic complicating diseases of diabetes.Though the diabetes pill annual sales amount that existing market is sold surpasses hundred million yuan, is the major product of hypoglycemic pcm, diabetes pill is the Chinese medicine and western medicine mix preparation, uses to have in a large number for a long time to cause " hypoglycemic reaction " side effect, and diabetic vascular complications is not had obvious effect.

Therefore, exploitation can blood sugar lowering, can treat the Chinese patent medicine of chronic complicating diseases of diabetes again, can maximize favourable factors and minimize unfavourable ones, and greatly improves the competitiveness of product in market, fills a hole in the market, and produces good social benefit, obtains considerable economic.

[summary of the invention]

The object of the present invention is to provide a kind of effectively blood sugar lowering, can treat the new Chinese medicine of chronic vascular complications such as diabetes complicated hyperlipidemia, high blood viscosity and its preparation method again.

The object of the present invention is achieved like this: a kind of pharmaceutical composition for the treatment of diabetes is characterized in that it is mainly made Rhizoma Coptidis 2-6 part, Rhizoma Polygoni Cuspidati 2-6 part, Cortex Cinnamomi 0.5-3 part by following bulk drugs.

This preparation of drug combination method may further comprise the steps:

A) 2-6: 2-6 by weight ratio; 0.5-3 it is standby to take by weighing Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cortex Cinnamomi respectively;

B) Rhizoma Coptidis, Rhizoma Polygoni Cuspidati adopt alcohol reflux, form extract powder, and Cortex Cinnamomi is extracted volatile oil;

C) volatile oil is mixed with extract powder, add adjuvant, shape.

Type ii diabetes belongs to the Chinese medicine chronic vascular complications such as category, type ii diabetes Chang Bingfa hyperlipidemia, high blood viscosity, sclerosis of blood vessels of " quenching one's thirst ".Lung gastric heat symptom-complex shapes such as existing clinically thirsty polydipsia, vexed insomnia, the easy flesh of polyphagia have weakness of the spleen and kidney symptoms such as weak, that become thin (or fat), clear urine in large amounts or nocturia are frequent again.Along with the delay of the course of disease, weakness of the spleen and kidney, insufficiency of primordial QI, the deficiency of vital energy is the promoting the circulation of blood of disablement Tianjin then, grows turbid, the blood stasis of expectorant; And lung gastric heat, consumption impairment of QI the moon promote blood stasis, the generation that expectorant is turbid; The turbid heresy of the stasis of blood is moving with air-flow, nowhere less than, block the brain network and dizziness headache, limbs unsuccessful (diabetic cerebral arteries pathological changes) very then then occur, block the eye network and blurred vision (diabetic retinopathy) then occurs, then uncomfortable in chest, the chest pain (diabetic cardiopathy) of numbness resistance breast sun, numbness resistance kidney network then the kidney flatusization with distinguish not turbid merit (diabetic nephropathy), block extremity and numb limbs and tense tendons (diabetic limb artery sclerosis) etc. then occurs.Therefore, we think: diabetes (type ii diabetes) is the disease of the real deficiency in origin of a mark, and mark is real carries throughout based on lung (heart) dryness of the stomach heat, blood stasis, and what deficiency in origin was outstanding shows as a little less than the gas of suffering from a deficiency of the kidney.Above-mentioned pathogenic characteristic at type ii diabetes (diabetes), we adopt heat clearing and blood circulation promoting with take stopgap measures, the kidney invigorating holds up unit with the method for effecting a permanent cure control type ii diabetes and vascular complications such as hyperlipidemia, high blood viscosity thereof, hand in traditional classical prescription to add with Rhizoma Polygoni Cuspidati on the basis of safe ball and formed this compound medicine.

The present invention's (pharmaceutical composition) is made up of medicines such as Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cortex Cinnamomis.Each medicine proportion compatibility is 2-6: 2-6: 0.5-3, and after aforementioned pharmaceutical compositions took by weighing in proportion, Rhizoma Coptidis, Rhizoma Polygoni Cuspidati adopted alcohol reflux, form extract powder, Cortex Cinnamomi is extracted volatile oil, and volatile oil is mixed with extract powder, add adjuvant, promptly get the present invention's (pharmaceutical composition) powder agent after the drying.

Rhizoma Coptidis clearing away heat-fire in the side, " book on Chinese herbal medicine justice " meaning " Rhizoma Coptidis big bitter Great Cold ... the heat of the heart, spleen, liver, kidney, the fire of gallbladder, stomach, intestine and small intestine is controlled it invariably." Rhizoma Coptidis clearing away heat-fire power Sheng; the pathogenesis for diabetes heart-fire Yu Sheng, exuberant lung-stomach heat, fire (dry) thermal burn the moon extremely agrees with; so have: the record of saying (" Mingyi Bielu "), " control and quench one's thirst, steam Rhizoma Coptidis with wine " of " Rhizoma Coptidis ... only quench one's thirst " (" book on Chinese herbal medicine is order just ").Modern pharmacological research confirms: berberine is that berberine is the main component of Rhizoma Coptidis, content is up to 5%--8%, berberine can reduce the blood glucose of normal mouse and alloxan diabetes mice and spontaneous diabetic mice, simultaneously to rat insulin opposing model, Rhizoma Coptidis have the effect that strengthens insulin sensitivity, and it is unusual that berberine can also obviously improve the lipid metabolism of experimental type ii diabetes mice.

Rhizoma Polygoni Cuspidati blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing in the side.The Rhizoma Polygoni Cuspidati bitter cold is apt to away blood system, can control that blood vessels, removing blood stasis with potent drugs coagulate, the water that stimulates the menstrual flow, and its property is high strong." Mingyi Bielu " record: " Rhizoma Polygoni Cuspidati master tonneau moon water, broken stagnant blood crux ", " Japan hanako materia medica " record " is managed property the back stagnant blood not down, trusted subordinate's distension ... pounce on and decrease blood stasis ", and Compendium of Material Medica is carried Rhizoma Polygoni Cuspidati " it is irritated to control big heat, quenches the thirst ".Rhizoma Polygoni Cuspidati and Rhizoma Coptidis mutually 5, not only brought into play promoting blood circulation to restore menstrual flow merit, but also strengthen the power of Rhizoma Coptidis clearing away heat-fire, the collaborative mark reality of removing type ii diabetes (diabetes) dryness-heat being excessive in the interior, blood-stasis internal-depression.The amber cane contains multiple pharmacological component, and its main effective ingredient polidatin has effects such as the blood vessel of expansion, antithrombotic, blood fat reducing and antioxidation; And the Rhizoma Polygoni Cuspidati tannin has good hypoglycemic activity.

Unit is held up in the Cortex Cinnamomi the kidney invigorating in the side.Cortex Cinnamomi suffering, sweet, big heat, kind guiding fire to origin, the kidney invigorating unit be deficient, inspire QI and blood growth, tonneau battalion to defend blood vessels.Compendium of Material Medica is thought: " Cortex Cinnamomi is descending, nourishing renal yang to restrict excessive yin, and this permanent so-called kidney hardship in east is dry, and anxious food is hot moistening it, loosing the interspaces of skin and muscles, bringing about the spread of body fluid, logical its gas person are also "." property of medicine class the moon " meaning: " yang-energy can be guided in osmanthus, a surname's promoting blood circulation ".And " book on Chinese herbal medicine is looked for the truth " record: " its color purple is red for Cortex Cinnamomi, the sweet suffering of abnormal smells from the patient, and the energy of inspiring vim and vigour is arranged, the pure sun of gonosome, the power that has the guiding of recruiting to lure ".Cortex Cinnamomi is joined Rhizoma Coptidis, and name is handed over safe ball, and the merit of restoring normal coordination between the heart and kidney is arranged, can on the clear away heart-fire heat of stomach, the void of following the kidney invigorating unit; Cortex Cinnamomi 5 Rhizoma Polygoni Cuspidati can be assisted the power of its blood circulation promoting and blood stasis dispelling, current blood vessels.Modern pharmacological research confirms: Cortex Cinnamomi volatile oil can significantly reduce the blood glucose of alloxan diabetes mice; In experiment in vitro, cinnamomic water solubility extract can increase the absorption of glucose and activate glycogen synthetic, increase the phosphorylation of Insulin receptor INSR, and have and help trigger the insulin cascade system, Cortex Cinnamomi also has blood vessel dilating, antithrombotic pharmacological action.

Rhizoma Coptidis in this compound medicine, Rhizoma Polygoni Cuspidati, Cortex Cinnamomi three medicines mutually 5 in a word, simultaneously using both cold and hot drugs with regulating yin and yang, rush down and mend the colleague to take into account deficiency and excess, help the recovery of the deficiency in origin of diabetes (type ii diabetes) is scorching, the mark of blood stasis is real removing, kidney unit, the side demonstrate,proves and conforms to.And modern pharmacological research confirms: all contain the pharmacological component of blood sugar lowering in Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, the Cortex Cinnamomi, have pharmacologically active effects such as blood fat reducing, antithrombotic, antioxidation, blood vessel dilating simultaneously respectively.Therefore, we had both met instruction of Chinese Medicine theory for the treatment of chronic vascular complications such as the concurrent hyperlipidemia of type ii diabetes, high blood viscosity, had the pharmacology objective basis again.

Diabetes (type ii diabetes) is the disease of the real deficiency in origin of a mark, and mark is real carries throughout based on lung (heart) dryness of the stomach heat, blood stasis, and what deficiency in origin was outstanding shows as a little less than the gas of suffering from a deficiency of the kidney.Pharmaceutical composition of the present invention have heat clearing and blood circulation promoting with take stopgap measures, the kidney invigorating holds up the effect of unit to effect a permanent cure, our prescription is simplified, and hands in traditional classical prescription to add on the basis of safe ball and use Rhizoma Polygoni Cuspidati, tremble with fear Wen Tongyong, adopting both clearing heat method and tonification method and the merit of current blood vessels is all arranged.Type ii diabetes being merged chronic blood vessels such as blood fat raises, hemorheology is unusual, vasomotor dysfunction, to close the complication curative effect outstanding.

[description of drawings]

Fig. 1: normal rats islets of langerhans, HE * 200;

Fig. 2: model group rat Langerhans islet, islets of langerhans atrophy, disappearance HE * 200;

Fig. 3: diabetes pill group rat Langerhans islet, beta Cell of islet vacuolar degeneration, HE * 200;

Fig. 4: low dose group rat Langerhans islet, beta Cell of islet vacuolar degeneration, HE * 200;

Fig. 5; Middle dosage group rat Langerhans islet, beta Cell of islet vacuolar degeneration, HE * 200;

Fig. 6: high dose group rat Langerhans islet, beta Cell of islet vacuolar degeneration, HE * 200.

[specific embodiment]

Embodiment 1: pharmaceutical composition of the present invention is mainly made by following bulk drugs, Rhizoma Coptidis 2-6 part, Rhizoma Polygoni Cuspidati 2-6 part, Cortex Cinnamomi 0.5-3 part.

A) by weight ratio 2-6: 2-6: 0.5-3 to take by weighing Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cortex Cinnamomi respectively standby;

B) Rhizoma Coptidis, Rhizoma Polygoni Cuspidati adopt alcohol reflux, form extract powder, and Cortex Cinnamomi is extracted volatile oil;

C) volatile oil is mixed with extract powder, add adjuvant, be processed into peroral dosage form.

For example: can be processed into granule (granule or powder preparation to be taken after being infused in boiling water), tablet (plain sheet, coated tablet, dispersible tablet, fast disintegrating tablet, effervescent tablet etc.), capsule (hard capsule, soft capsule), oral fluid agent.

Embodiment 2:

Took by weighing Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cortex Cinnamomi in 4: 4: 1.5 by weight ratio respectively, all the other steps make the present invention's (pharmaceutical composition) with embodiment 1.

Embodiment 3:

Took by weighing Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cortex Cinnamomi in 2: 2: 0.5 by weight ratio respectively, all the other steps make the present invention's (pharmaceutical composition) with embodiment 1.

Embodiment 4:

Took by weighing Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cortex Cinnamomi in 6: 6: 3 by weight ratio respectively, all the other steps make the present invention's (pharmaceutical composition) with embodiment 1.

The present invention's (pharmaceutical composition) observes diabetes rat blood sugar lowering and protection vascular effect

Experiment material:

1, laboratory animal: healthy male wister rat, the SPF level, 70, body weight 250 ± 20g, available from Nanfang Medical Univ (former No.1 Military Medical Univ.) Experimental Animal Center, laboratory animal Certificate Of Conformance number: 0005201.

2, experiment medicine: the present invention's (pharmaceutical composition) preparation (Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cortex Cinnamomi) is provided by Guangdong Province's Chinese medicine institute TCM Research Office, and every 1g medicated powder is equivalent to crude drug 4.77g, lot number: 050301; Positive control drug one diabetes pill (per 10 heavy 2.5g, wherein the content of glyburide is 2.5mg) provide lot number by Guangzhou No.1 Chinese Pharmacy Factory production, Guangzhou pharmaceuticals:: the accurate word Z44020045 of traditional Chinese medicines.

3, modeling medicine: streptozotocin: U.S. sigma company produces, import packing, the supply of Guangzhou Bo Li biotech firm.Cholesterol: import packing, German company production, the supply of Guangzhou southization glass company; Adeps Sus domestica, yolk powder are supplied by Guangzhou food company.

4, animal facility: experiment is carried out at the SPF of Experimental Animal Center zoopery portion of Zhongshan University (cleaning level) laboratory, the experimental situation quality certification number: the Guangdong word 2004B029 that checks and affirm, animal facility is used proof number: 0001066.

5, experimental apparatus and reagent:

5.1 key instrument: ONETOUCH Ultra blood sugar monitoring instrument, U.S. Lifescan company, the medical device company limited import of Shanghai Johnson ﹠ Johnson; The CX5--automatic clinical chemistry analyzer, U.S. Beckman company; Automation-tissue-dehydrating machine, full-automatic embedding machine, full-automatic slicing machine, full-automatic dyeing machine, German Lycra company; 752 uv-spectrophotometric instrument, Shanghai the 3rd analytical tool factory; Radioimmunoassay instrument, DFM-96 type, multitube radioimmunity enumerator (10 probe), the many one-tenth in Hefei ,Anhui mechanical ﹠ electrical technology corporation; Full-automatic vertebral plate formula blood viscosity instrument, Beijing generation Supreme Being company.

5.2: main agents: blood sugar test reagent, U.S. U.S. Lifescan company produces, the medical device company limited import of Shanghai Johnson ﹠ Johnson; Cholesterol (2-204C), triglyceride (2-213C),, high density lipoprotein (2-179C), low density lipoprotein, LDL (2-180C), blood urea nitrogen (2-206C), serum creatinine test kits such as (2-230B) produced by Ke Mei Bioisystech Co., Ltd of Beijing China and Sweden; The total protein titer; Germany Human company produces; The insulin assay test kit, the Beijing North biotechnology research is produced, authentication code: the accurate word of traditional Chinese medicines: S-10930046; 20050701,20050602 superoxide dismutase detection, malonaldehyde, nitric oxide detection kit are built up bio-engineering research by Nanjing and are produced lot number:,

Experimental technique:

1, modeling method: in 4 weeks of animal feeding, body weight increases to 250 ± 20g, and the reference literature reported method adds the feeding high fat diet with the injection streptozotocin and duplicates the high fat rat model of diabetes.Be specially dosage disposable celiac injection streptozotocin (STZ with 50mg/kg, with the sodium citrate solution dilution, ph 4.0, fresh preparation in the ice chest), surveys blood glucose behind the 72h, with fasting 6h blood glucose 〉=16.7mmol/L person, be diabetes rat, play giving rat high fat diet (conventional feed adds 2% cholesterol, 10% Adeps Sus domestica, 5% yolk powder) every day next day, fed for 12 weeks altogether, duplicate the high fat rat model of diabetes.

2, experiment grouping and dosage: select 50 of diabetes rats, be divided into the safe and sound high, medium and low dosage group of sugared arteries and veins at random, the positive drug matched group, model control group, is established 10 of normal control rats by 10 every group.The high dose group dosage is 1.8g/kg: middle dosage group dosage is 0.6g/kg, the low dosage dosage is 0.2g/kg, the dosage of sun medicine contrast medicine diabetes pill is equivalent to clinical equivalent dosage (middle dosage), be 0.7g/kg, the said medicine distilled water diluting, the administration capacity is the 2ml/100g body weight, and model group, normal group give the distilled water of same capability.Except that normal observation group, administration gives the rat high fat diet simultaneously, every day administration time 8-9am, administration is 6 days weekly, totally 12 weeks.

3, index observing:

3.1 the blood sugar lowering effect is observed:

3.1.1: blood glucose: first week, the 6th week, the 12 week (experiment finish before) behind experimental drug respectively,

5 treated animal fasting (freely drinking water) such as simple model group, diabetes pill group, low dose group, middle dosage group, high dose group 6 hours, measure behind the blood glucose gastric infusion immediately, blood glucose value (glucose oxidase method is measured in administration after 2 hours, microcomputer detects), unit represents with mmol/L, respectively organizes the variation of administration front and back blood glucose value; 12 week of medication back (experiment finish before) empty stomach changes of blood glucose when fasting glucose becomes mould with diabetes relatively simultaneously.

3.1.2: serum insulin: before experiment finishes, each treated animal fasting 6 hours, the back etherization of weighing, abdominal aortic blood, separation of serum is used the serum measured by radioimmunoassay insulin active.Unit represents with uIU/ml.

3.1.3: islets of langerhans pathology: after each treated animal is got blood, dislocation is put to death, separate pancreas, get portion of tissue near head of pancreas, use 10% formalin fixed, the paraffin embedding section, HE dyeing, the islets of langerhans number of variations is observed in 100 times of visuals field of light microscopic down, and every example is observed 5 visuals field, and observation islets of langerhans pathomorphism changes.

3.2: the protection vascular effect is observed

3.2.1 blood fat, blood viscosity: each is organized when experiment finishes, etherization, abdominal aortic blood 1ml, separation of serum, detect with enzyme process, turbidimetry respectively on the CX5 automatic clinical chemistry analyzer and respectively organize variations such as cholesterolemia, triglyceride, HDL-C, low-density lipoprotein cholesterol, unit represents with mmol/L; Taking heparin anticoagulation 1ml respectively organizes the whole blood viscosity value with the fully automatic blood viscosity apparatus detection of Beijing generation Supreme Being company and changes

3.2.2 antioxidation index: each is organized when experiment finishes, and uses etherization, abdominal aortic blood 2ml, and separation of serum detects the blood superoxide dismutase activity with xanthine oxidase, and unit represents with u/ml; Detect lipid peroxide concentration metabolite one malonaldehyde level with thiobarbituricacid method (TBA), unit represents with nmol/ml.

3.2.3, organize aldose reductase activity: each is organized when experiment finishes, and puts to death animal, gets a part renal cortex and a branch hole ball, detects kidney and crystalline lens etc. with ultraviolet spectrophotometry and organizes aldose reductase activity.

3.2.4 renal function changes: each is organized when experiment finishes, and collects the 24h urine with metabolic cage, and is centrifugal, detects twenty-four-hour urine albumen with sulfosalicylic acid-sodium sulfate turbidimetry, and unit represents with g/L; Use etherization, abdominal aortic blood 2ml, separation of serum detects blood urea nitrogen content with performance rate method, enzyme process, and unit represents with mmol/L.

Put to death animal, get two kidneys, remove peplos and weigh, calculate kidney weight/body weight, unit represents with %; Get the part nephridial tissue, detect the kidney nitric oxide level with nitrate reductase method, unit represents with nmol/ml.Experimental result:

One, blood sugar lowering effect

(1) the present invention (pharmaceutical composition) is to the influence (seeing Table 1-4) of the high fat rat model of diabetes blood glucose

It can be seen from the table, during the blood sugar lowering effect in first week, the 6th week, the 12 week (when experiment finishes) is observed after medication, each dosage group of the present invention's (pharmaceutical composition), positive drug matched group all have the effect that blood glucose is reduced, there was no significant difference (P＞0.05) between each medication group group, each medication group and model group contrast, significant difference (P＜0.05); Compare with fasting glucose average before the experimental drug, fasting glucose average after 12 weeks of medication, model group has risen 15.72%, the present invention's (pharmaceutical composition) respectively organizes and positive drug matched group blood sugar level is basicly stable and downward trend is arranged, obvious with the effect of the present invention's (pharmaceutical composition) high dose group, each group and model group ratio, significant difference (P＜0.05).Prompting the present invention (pharmaceutical composition) induces to add to streptozotocin and feeds that the instant medication of the high fat rat model of diabetes has significant blood sugar lowering effect, long-term prescription that significantly stable or blood sugar lowering effect are arranged due to the high fat.

Table 1: instant change of blood sugar before and after the high fat rat model first all administrations of diabetes (X ± S)

Grouping	N	Before the medicine (mmol/L)	After the administration (mmol/L)	Difference in means	Decline percentage ratio (%)
						Dosage group high dose group in the model group diabetes pill group low dose group	10 10 10 10 10	22.82±2.58 22.51±2.28 23.57±2.80 24.36±3.39 25.38±2.61	21.74±2.67 19.28±2.23 * 20.02±1.61 * 20.60±3.32 * 21.30±2.08 *	1.08 3.23 3.55 3.76 4.08	4.72 14.35 15.06 15.44 16.08

With compare before the medicine, ^*P＜0.05

Table 2: instant change of blood sugar before and after high fat rat model the 6th all administrations of diabetes (X ± S)

Grouping	N	Before the medicine (mmol/L)	After the administration (mmol/L)	Difference in means	Decline percentage ratio (%)
						Dosage group high dose group in the model group diabetes pill group low dose group	10 10 10 10 10	23.18±4.55 24.27±4.81 23.45±5.65 25.38±4.79 26.21±3.29	21.78±4.19 20.73±4.88 * 19.12±5.76 * 20.71±4.74 * 21.03±4.27 *	1.40 3.97 4.24 4.67 5.18	6.04 16.36 18.08 18.4 19.76

With compare before the medicine, ^*P＜0.05

Instant changes of blood glucose before and after table 3, high fat rat model the 12 all administrations of diabetes (X ± S)

Grouping	N	Before the medicine (mmo1/L)	After the administration (mmol/L)	Difference in means	Decline percentage ratio (%)
						Dosage group high dose group in the model group diabetes pill group low dose group	9 10 9 9 10	26.21±3.60 23.25±3.26 22.40±4.60 23.76±5.06 22.94±4.84	24.54±1.95 19.47±2.96 * 19.01±3.86 * 19.72±3.41 * 18.85±3.96 *	1.67 3.78 3.39 4.04 4.09	6.37 16.25 15.13 17.0 17.83

With group contrast before the medicine, ^*P＜0.05

Table 4: the variation of rat blood sugar before and after 12 weeks of the high fat rat model of diabetes administration

Grouping	Before the administration (mmol/L)	Administration 12 week backs (mmol/L)	Difference in means	Change percentage ratio (%)
					Dosage group high dose group in the model group diabetes pill group low dose group	22.65±2.91 23.42±3.61 23.84±3.46 24.89±3.36 25.15±2.6	26.21±3.59 * 23.25±3.26 22.4±4.60 23.76±5.06 322.94±4.84 *	3.56 -0.17 -1.14 -1.13 -2.21	15.72％ -0.73％ -4.78％ -4.54％ -8.79％

With group contrast before the administration, ^*P＜0.05

(2) to the influence (seeing Table 5) of diabetes high fat rat blood serum insulin level and islets of langerhans number (pathology)

As seen from Table 5, model group serum insulin levels and islets of langerhans number are starkly lower than normal control group (P＜0.05), and each dosage group of the present invention's (pharmaceutical composition) and positive control medicine diabetes pill group are compared the effect that stable serum insulin levels is all arranged and stablize the islets of langerhans number with model group, with the effect of the middle and high dosage group of the present invention's (pharmaceutical composition) obvious (P＜0.05).

Pancreas pathomorphism finding: normal group pancreas α, β cell are clear, islets of langerhans is not seen hypertrophy or atrophy, the atrophy of the most sample islets of langerhans of model group, disappearance, a few sample beta Cell of islet vacuolar degeneration, each dosage group of the present invention's (pharmaceutical composition), each sample standard deviation of positive control medicine diabetes pill group are seen the pancreas beta Cell of islet vacuolar degeneration of degree varies, a small amount of atrophy.See accompanying drawing 1-6.Prompting the present invention (pharmaceutical composition) has protective effect to the islets of langerhans damage due to the streptozotocin.

To sum up, the present invention (pharmaceutical composition) reduces or stable blood sugar effect and the impaired islets of langerhans of its protection, to stablize serum insulin levels relevant.

Table 5: the influence of the present invention's (pharmaceutical composition) diabetes high fat rat blood serum insulin level and islets of langerhans number

Grouping	Serum insulin (uIU/m1)	Islets of langerhans number (individual/visual field)
			Dosage group high dose group in the normal group model group diabetes pill group low dose group	32.19±8.71 * 15.76±4.47 20.82±7.18 21.80±7.77 22.88±5.46 * 24.88±6.23 *	7.56±3.28 * 2.00±1.58 3.40±1.78 2.78±1.20 4.00±1.66 * 4.33±2.35 *

Compare with model group, ^*P＜0.05;

Two, vascular protection effect

(1) the present invention (pharmaceutical composition) is to the influence (seeing Table 6) of the high fat rat fat of diabetes

Diabetes complicated dyslipidemia particularly cholesterol rising is to cause the independent hazard factor of vascular lesions such as atherosclerosis as seen from Table 6, compare with model group, each dosage group of the present invention's (pharmaceutical composition) can obviously reduce blood T-CHOL and the low-density lipoprotein cholesterol level of the high fat rat of diabetes, and the effect of certain triglyceride reducing arranged, each dosage group of reduction of blood T-CHOL there is certain dose-effect dependence.The effect of positive control medicine diabetes pill reduction cholesterolemia and triglyceride is not obvious.The phenomenon that the HDL-C of model group and each medication group has compensatory to raise.

Table 6: the present invention's (pharmaceutical composition) is to the influence of the high fat rat fat of diabetes (X ± S)

Grouping	N	TC (mmol/L)	TG (mmol/L)	HDL-C (mmol/L)	LDL-C (mmol/L)
						Dosage group high dose group in the normal group model group diabetes pill group low dose group	9 9 10 9 9 9	1.65±0.20 * 15.97±8.95 10.90±9.14 5.81±3.67 * 5.12±1.79 * 4.61±2.25 *	0.56±0.14 * 1.97±1.45 1.38±1.11 1.34±0.67 1.04±0.49 0.92±0.39 *	1.25±0.16 * 3.07±1.55 2.56±1.17 2.32±0.47 2.14±0.68 1.80±0.37 *	0.38±0.05 * 13.97±9.71 9.38±7.89 3.27±3.43 * 3.60±1.71 * 3.26±1.85 *

Compare with model group, ^*P＜0.05;

(2) the present invention (pharmaceutical composition) is to the influence (seeing Table 7) of the high fat rat of diabetes whole blood viscosity

Whole blood viscosity under the high shear rate mainly is that red cell deformability produces, and height is cut the viscosity height, erythrocyte deformability or poor flexibility, and the blood vessel wall sclerosis is crude, and the relation of red cell deformability and microangiopathies is more close.As seen from Table 10, compare with model group, each dosage group of the present invention's (pharmaceutical composition) can obviously reduce each shear rate value of whole blood viscosity of the high fat rat of diabetes, particularly, be certain dose-effect dependence to having high shear rate value (the whole blood 200 ') effect of the whole blood viscosity of substantial connection to give prominence to the diabetes microvascular complication.The present invention's (pharmaceutical composition) is better than positive control medicine diabetes pill to the whole blood viscosity effect trend of high shear rate.

Table 7: the present invention's (pharmaceutical composition) is to the influence of the high fat rat of diabetes whole blood viscosity (X ± S)

Grouping	N	Whole blood 200 '	Whole blood 30 '	Whole blood 5 '	Whole blood 1 '
						Normal group	9	3.94±0.48 *	5.52±0.60 *	10.31±1.10 *	25.18±3.13 *

Dosage group high dose group in the model group diabetes pill group low dose group

9 10 9 9 10

6.78±0.66 5.14±1.62 * 4.82±1.29 * 4.46±0.77 * 4.29±0.31 *

8.61±0.84 6.80±2.17 * 6.53±1.75 * 5.97±1.04 * 5.97±0.37 *

13.76±1.37 11.64±3.78 11.55±3.12 * 10.38±1.87 * 11.04±0.68 *

31.63±2.96 25.91±8.58 * 26.64±7.27 23.53±4.43 * 26.67±2.20 *

Compare with model group, ^*P＜0.05

(3) the present invention (pharmaceutical composition) is to the influence (seeing Table 8) of the high fat rat serum of diabetes SOD, MDA

Under the high smectic attitude of diabetes, antioxidant ability of organism is low, and blood vessel endothelium easily causes oxidative damage.As seen from Table 8, compare with model group, the present invention's (pharmaceutical composition) can obviously improve the blood oxide dismutase activity of the high fat rat of diabetes, suppresses lipid peroxide metabolite MDA content.And positive control medicine diabetes pill is compared there was no significant difference (P＞0.05) to the influence of mda content with model group.

Table 8: the present invention's (pharmaceutical composition) is to the influence of the high fat rat model of diabetes blood SOD, MDA (X ± S)

Grouping	N	SOD (u/ml)	MDA (nmol/m1)
				Dosage group high dose group in the normal group model group diabetes pill group low dose group	9 9 10 9 9 10	208.13±49.10 * 172.30±23.09 180.18±37.94 199.63±17.12 238.32±59.90 * 268.26±18.15 *	5.77±1.34 * 7.92±2.80 7.06±2.11 6.61±1.84 * 6.82±1.05 * 6.41±1.07 *

Compare with model group, ^*P＜0.05,

(4) the present invention (pharmaceutical composition) is to the influence (seeing Table 9) of the high fat of diabetes rat tissue aldose reductase activity

Under the hyperglycemia state, crystalline lens and kidney aldose reductase activity raise, and are the major reasons that causes diabetic eye, kidney microvascular complication.As seen from Table 9, the AR activity of the crystalline lens of model group and kidney is obviously than normal group obviously raise (P＜0.05), each dosage group of the present invention's (pharmaceutical composition) has obvious reduction crystalline lens AR active function (P＜0.05), to active the present invention of kidney AR (pharmaceutical composition) certain reduction effect is also arranged, with high dose group effect obviously (P＜0.05).The diabetes pill group has the effect trend of reduction to crystalline lens and kidney AR activity, compares there was no significant difference with model group.Prompting the present invention (pharmaceutical composition) has the reduction aldose reductase activity, the effect of microvascular complications such as prevention eye, kidney.

Table 9: the present invention's (pharmaceutical composition) is to the active influence of the high fat AR of rat tissue of diabetes (X ± S)

Grouping	N	Crystalline lens AR	Kidney AR
				Dosage group high dose group in the normal group model group diabetes pill group low dose group	9 9 9 9 9 10	0.21±0.05 * 0.27±0.04 0.24±0.07 0.21±0.03 * 0.15±0.04 * 0.16±0.07 *	0.67±0.24 * 1.10±0.5 1.06±0.4 0.99±0.5 0.92±0.37 0.72±0.28 *

Compare with model group, ^*P＜0.05,

(5) the present invention (pharmaceutical composition) is to the influence (seeing Table 10-11) of the high fat rat kidney of diabetes index, renal function (urine protein, blood urea nitrogen etc.)

Diabetic nephropathy is the main microvascular complications of diabetes, be feature with HT pressure, the high filtration in the glomerule in early days, show as kidney enlargement, the increase of nephridial tissue nitric oxide, Microalbuminuria etc., the increase of the early stage NO level of diabetic nephropathy and glomerular filtration rate increase and are proportionate.

As seen from Table 11, compare with normal group, the high fat kidney of rats of diabetes weight/body weight (kidney index) obviously increases, and the kidney weight/body weight of each group of the present invention's (pharmaceutical composition) all is starkly lower than model group (P all＜0.05).

As seen from Table 12, compare with model group, each dosage group of the present invention's (pharmaceutical composition) organizes nitric oxide and twenty-four-hour urine albumen that obvious reduction effect (P all＜0.05) is all arranged to the high fat kidney of rats of diabetes, and the middle and high dosage group of the present invention's (pharmaceutical composition) is to blood urea nitrogen effect obvious (P＜0.05); The control drug diabetes pill does not show (P＞0.05) to effects such as nephridial tissue nitric oxide, urine protein, blood urea nitrogen.

Prompting the present invention (pharmaceutical composition) has the early stage injury of kidney of the high fat rat of diabetes and reduces kidney one nitrogenize nitrogen level, alleviates that renal swelling expands, the effect of renal function protecting.

Table 11: the present invention's (pharmaceutical composition) is to the high fat kidney of rats weight of diabetes, body weight, the influence of kidney weight/body weight

(X±S)

Grouping	N	Kidney heavy (g)	Body weight (g)	Kidney weight/body weight (%)
					Dosage group high dose group in the normal group model group diabetes pill group low dose group	9 9 10 9 9 10	2.72±0.44 * 3.38±0.68 3.22±0.39 2.96±0.73 3.03±0.35 2.59±0.33 *	433.89±29.98 * 286.67±47.10 277.80±41.41 261.67±45.41 278.89±28.59 257.00±38.74	0.63±0.09 * 1.21±0.34 1.17±0.07 1.09±0.16 * 1.09±0.12 * 1.03±0.18 *

Compare with model group, ^*P＜0.05

Table 12: to the influence of the high fat kidney of rats of diabetes nitric oxide, urine protein, blood urea nitrogen (X ± S)

Grouping	N	NO (umol/L)	UP24 (g/L)	BUN (mmol/L)
					Dosage group high dose group in the normal group model group diabetes pill group low dose group	9 9 10 9 9 9	3.94±1.27 * 8.40±3.32 7.00±2.64 5.86±2.07 * 6.48±2.94 * 5.04±1.92 *	0.0156±0.017 * 0.0833±0.047 0.0740±0.035 0.0411±0.031 * 0.0489±0.026 * 0.0250±0.0171 *	6.829±2.170 * 12.089±3.819 11.025±1.512 10.562±1.741 10.124±2.525 * 8.776±2.438 *

Compare with model group, ^*P＜0.05

Conclusion:

1, the present invention (pharmaceutical composition) induces streptozotocin and increases the high fat rat of diabetes that fat feeds and have and reduce significantly or stable blood sugar effect, and its blood sugar regulation effect is impaired with the islets of langerhans due to the present invention's (pharmaceutical composition) protects modeling, it is relevant to stablize serum insulin levels.

2, the present invention (pharmaceutical composition) has satisfied reduction cholesterolemia and low-density lipoprotein cholesterol to the high fat rat of diabetes; improve whole blood viscosity, improve the effect of body antioxidative; thereby help protecting tunica intima, improve blood circulation, prevent formation, the development of diabetes complicated sclerosis of blood vessels, pathological changes such as narrow.

3, the present invention (pharmaceutical composition) has satisfied reduction kidney, eye aldose reductase activity to the high fat rat of diabetes, reduce the nephridial tissue nitric oxide level, improve effect such as renal function, thereby help preventing formation, the development of diabetes microvascular complications such as kidney, eye.

To sum up, the present invention's (pharmaceutical composition) induces streptozotocin and increases the high fat rat of diabetes that fat feeds and have blood sugar lowering effect significantly, has simultaneously to protect blood vessel satisfactorily, improve blood circulation, prevent the effect of vascular complication.

Claims (3)

1, a kind of pharmaceutical composition for the treatment of diabetes is characterized in that it is made Rhizoma Coptidis 2-6 part, Rhizoma Polygoni Cuspidati 2-6 part, Cortex Cinnamomi 0.5-3 part by following bulk drugs.

2, a kind of preparation of drug combination method for the treatment of diabetes, it may further comprise the steps:

A) by weight ratio 2-6: 2-6: 0.5-3 to take by weighing Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cortex Cinnamomi respectively standby;

B) Rhizoma Coptidis, Rhizoma Polygoni Cuspidati adopt alcohol reflux, form extract powder, and Cortex Cinnamomi is extracted volatile oil;

C) volatile oil is mixed with extract powder, add adjuvant, shape.

3, preparation method according to claim 2 is characterized in that peroral dosage form is processed in Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cortex Cinnamomi extraction, comprises granule, tablet, capsule, oral fluid agent.

Images